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Introduction: Recent studies show an association between autoimmune thyroiditis and sys-
temic  sclerosis (SSc) and suggest that this condition may interfere with the ES phenotype.
However these studies evaluate the autoimmune thyroiditis as a whole and none of them
speciﬁcally addresses Hashimoto’s thyroiditis (HT) in SSc.
Objective: To investigate the presence of HT in SSc patients and its possible association with
disease manifestations.
Methods: Clinical manifestations of hypothyroidism, TSH and anti-thyroid auto antibodies
(anti-TPO. anti TBG and TRAb) were studied in 56 patients with SSc. SSc patients with HT
were  compared with SSc patients without thyroiditis.
Results: HT was observed in 19.64% of patients with SSc. No association was observed
between HT and the different forms of disease or proﬁle of autoantibodies. Likewise, there
was  no difference between the mean modiﬁed Rodnan score and presence of Raynaud’s
phenomenon, scars, digital necrosis, myositis, arthritis, sicca symptoms, esophageal dys-
motility and scleroderma renal crisis when the groups were compared. On the other hand,
patients with HT had higher frequency of pulmonary hypertension in relation to patients
without HT (66.6% vs 22.5%, p = 0.016).
Conclusions: In the studied sample patients with ES and HT had higher prevalence of pul-
monary hypertension. Long-term follow-up studies with a larger number of TH and SScpatients are needed to conﬁrm these data.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Tireoidite  de  Hashimoto  pode  estar  associada  a  um  subgrupo  de
pacientes  de  esclerose  sistêmica  com  hipertensão  pulmonar
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r  e  s  u  m  o
Introduc¸ão: Estudos recentes mostram associac¸ão entre tireoidites autoimunes e esclerose
sistêmica (ES), e sugerem que essa condic¸ão pode interferir no fenótipo da ES. Entretanto,
esses estudos avaliam as tireoidites autoimunes como um todo e nenhum deles aborda
especiﬁcamente a tireoidite de Hashimoto (TH) na ES.
Objetivo: Investigar a presenc¸a de TH em pacientes com ES e sua possível associac¸ão com
as  manifestac¸ões da doenc¸a.
Casuística e métodos: Manifestac¸ões clínicas de hipotireoidismo, TSH, T4 livre e anticorpos
antitireoidanos (anti-TPO, anti TBG e TRAb) foram pesquisados em 56 pacientes com ES.
Pacientes com ES e TH foram comparados com pacientes com ES sem tireoidite.
Resultados: TH foi observada em 19,64% dos pacientes com ES. Não foi encontrada associac¸ão
entre a TH e as diferentes formas de doenc¸a ou com o perﬁl de autoanticorpos. Da  mesma
forma, não houve diferenc¸a entre a média do escore de Rodnan modiﬁcado e entre a
presenc¸a  de fenômeno de Raynaud, cicatrizes estelares, necrose digital, miosite, artrite,
sintomas sicca, dismotilidade esofágica ou crise renal esclerodérmica quando os grupos
foram comparados. Por outro lado, pacientes com TH apresentaram maior frequência de
hipertensão pulmonar quando comparados a pacientes sem TH (66,6% vs 22,5%; p = 0,016).
Conclusões: Na amostra de ES estudada, a TH está associada a uma maior prevalência de
hipertensão pulmonar. Estudos de seguimento a longo prazo, englobando um número maior
de  pacientes com ES e TH, são necessários para conﬁrmar esses dados.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
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he association among autoimmune diseases is common,
egardless if they are organ-speciﬁc or systemic.1 Thus, it
s necessary that the physician attending these patients
e aware of possible associations, not only for an early
iagnosis of such entities, but also to understand more  com-
letely the clinical manifestations that these patients may
ave.
Although there is no clear explanation for the association
etween autoimmune diseases, it is assumed that there is a
enetic predisposition to a common immune defect in many  of
hem.1 Among other possibilities, the exposure to some even-
ual infectious or environmental agent that acts as a triggering
actor of several diseases may be implicated.1
Hashimoto’s thyroiditis (HT) is the most common autoim-
une disease of the thyroid, being considered as a prototype
f organ-speciﬁc autoimmune diseases.2 HT presents with
arying degrees of glandular dysfunction, presence of anti-
hyroid antibodies and goiter or atrophy of the gland, and a
iffuse lymphocytic tissue inﬁltrate.2
On the other hand, SSc is a systemic autoimmune disease
haracterized by vasculopathy, excessive deposition of col-
agen in tissues and presence of autoantibodies.3 The exact
ole of autoantibodies in SSc is not well deﬁned,4 but it is
nown that they can inﬂuence the phenotype presented.4
ndeed, ﬂuctuations in topoisomerase I titles correlate with
kin thickening, assessed by the modiﬁed Rodnan score, and
ith disease activity, measured by clinical and laboratory
arameters.5 Interestingly, a subset of patients who devel-
ped negativity for this antibody showed less skin thickening,less lung involvement and better survival, when compared to
those persistently positive patients.6
SSc patients may have antibodies against thyroid antigens,
with or without gland dysfunction.7 A recent meta-analysis
showed that thyroid autoimmune disease was the more  com-
mon  organ-speciﬁc autoimmunity disease in patients with
SSc, with an estimated prevalence of 10.4%.8 The associa-
tion of SSc with anti-thyroid peroxidase antibodies is linked
to the presence of HLA-DR15.7 The connection of SSc with
other autoimmune diseases also seems to interfere with their
phenotype,4,8 affecting these patients with a milder form of
the disease. However, no study has speciﬁcally addressed the
association of SSc with HT. Thus, the aim of this study was to
investigate the presence of HT in SSc patients and its possi-
ble association with immunological and clinical proﬁles of the
disease.
Patients  and  methods
A cross-sectional study evaluating 56 consecutive patients
followed-up at an outpatient clinic of systemic sclerosis in
a single tertiary care hospital was conducted. Data were col-
lected from June 2012 to June 2013. All patients recruited met
the classiﬁcation criteria for SSc from ACR/EULAR 2013.9
The following manifestations of SSc were addressed:
Raynaud’s phenomenon, stellar scars, digital necrosis, skin
thickening according to the modiﬁed Rodnan score,10 arthri-interstitial pneumonitis, pulmonary hypertension and sclero-
derma renal crisis. Arthritis was considered as present when
at least one swollen joint was observed.11 The diagnosis of
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Table 1 – Clinical and serological proﬁle of 53 patients
with scleroderma.
n %
Raynaud 56/57 98.2
Stellar ulceration 34/56 60.7%
Digital necrosis 7/56 12.5
Telangiectasias 21/55 38.1
Rodnan (median) Variation of 0-50
(mean,
15.04 ± 10.19)
Myositis 8/54 14.8
Arthritis 21/56 14.8
Arthralgia 28/54 51.8
Xerostomia 25/52 48.08
Xerophthalmia 19/53 35.8
Esophageal dysmotility 29/53 54.7%
Interstitial lung disease 20/54 37.04
Pulmonary hypertension 15/49 30.6
Myocarditis 0
Renal crisis 3/55 5.4%
FAN 50/56 89.2
Anti-Scl70 8/55 14.55
Anti-centromer 12/52 24.08368  r e v b r a s r e u m a t
myositis was established by the presence of proximal mus-
cle weakness associated with at least one of the following:
increased CPK, EMG  with myopathic pattern, or biopsy with
myositis.11 Distal dysmotility or aperistalsis was considered
present when documented by manometry or seriography.11
Cardiac involvement was considered as caused by SSc when
presented in the form of pericarditis and/or heart failure,
or as an arrhythmia not attributed to other causes.11 Inter-
stitial lung disease was diagnosed when the forced vital
capacity was < 70% of the predicted, or ground-glass/ﬁbrosis
opacities were observed in thorax high-resolution tomogra-
phy scans.12,13 The diagnosis of pulmonary hypertension was
established when the systolic pulmonary artery pressure was
> 40 mmHg  observed in an echocardiogram, or the pulmonary
artery mean pressure was > 25 mmHg  with pulmonary artery
occlusion pressure < 15 mmHg.4,11
We  evaluated also the presence of ANA, anti-Scl 70, anti-
centromere, anti-Ro and anti-La. Clinical and laboratory data
were considered cumulatively positive. Disease severity was
assessed by Medsger index.14
The diagnosis of HT was performed in patients who
had hypothyroidism or goiter associated with the presence
of positive antibodies.4 To evaluate thyroid function, TSH
and free T4 were measured. The dosed antibodies were
anti-peroxidase (anti-TPO), anti-thyroglobulin (anti-TBG) and
anti-TSH receptor (TRAb). TSH and free T4 levels were
obtained by chemiluminescence, and values of 0.5-3.6 IU/mL
and 0.70-1.80 ng/dL were considered normal for TSH and free
T4, respectively. The anti-thyroid autoantibodies were also
investigated by chemiluminescence; and values <35 IU/mL for
anti-TBG; 40 IU/mL for anti-TPO; and 1.35 IU/L for TRAb were
considered as normal results.
The research protocol was approved by the local ethics
committee and all participants gave written informed con-
sent.
The data were presented as median and interquartile range
(IQR) if not normal, and as mean with standard deviation (SD)
if normal, according to the Kolmogorov-Smirnov test. When
some variable showed indications of normal distribution, we
used the Student’s t test for comparison between the means
of two continuous variables; when normality was rejected, we
used the Mann Whitney test for two continuous variables.
Categorical variables were compared using the chi-squared
test or Fisher’s exact test, when appropriate. A P-value
<0.05 was considered statistically signiﬁcant. All calcula-
tions were made with the aid of MedCalc software version
12.0.
Results
Description  of  the  sample
Fifty-six patients were studied: 52 women (92.8%) and four
men (7.1%), aged 19-81 years (median = 56; IQR of 39-61). In
this population, 33% were African descents (black and brown),
66% were Caucasians, and 1% had Indian ancestry. Regarding
the form of scleroderma, 19/56 (33.9%) patients had the diffuse
type, and 37/56 (66.1%) had the limited type. Approximately
39.6% were smokers.Anti-Ro 10/56 17.8
Anti-La 4/53 7.5
The autoantibody and clinical proﬁles of our population are
shown in Table 1.
The evaluation of the Medsger severity index was available
for 40 patients and ranged from 1 to 15, with a median of 5.0
(IQR, 4.0 to 7.75).
Anti-TPO antibody was present in 32.1%; anti-TBG in 18.8%;
and anti-TRAb in 11.4%. The diagnosis of HT was observed
in 19.64% of patients with SSc and all of them had hypothy-
roidism at diagnosis.
Comparison  of  SSc  populations  with  and  without  HT
No association between HT and the different forms of the
disease or autoantibody proﬁle was observed. Likewise, there
was no difference between the mean modiﬁed Rodnan score
and between the presence of Raynaud’s phenomenon, stel-
lar scars, digital necrosis, myositis, arthritis, sicca symptoms,
esophageal dysmotility and scleroderma renal crisis when the
groups were compared, as can be seen in Table 2. On the other
hand, patients with HT exhibited a higher frequency of pul-
monary hypertension when compared to patients without HT
(66.6% vs. 22.5; P = 0.016).
Discussion
There are several mechanisms associated with the occur-
rence of hypothyroidism in patients with SSc. The sclerosis
of the glandular tissue is one of them;15 the simultaneous
occurrence of autoimmune thyroid diseases is another.1
As previously mentioned, the association among several
autoimmune diseases is commonly observed, suggesting the
presence of common pathophysiological mechanisms in the
scenario of these conditions.1 Although the true events
involved in the pathogenesis of autoimmune diseases are
still uncertain, most of these patients have shown a genetic
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Table 2 – Comparative analysis of the population of scleroderma with and without Hashimoto’s thyroiditis (HT).
With HT
n = 11
Without HT
n = 45
P
Ethnicity Caucasian –63.6% (7/11) Caucasian – 65.9% (29/44) 0.31a
African descent – 36.3% (4/11) African descent – 31.82% (14/44)
Indian descent – 2.28% (1/44)
Gender Female/Male 10/1 42/3 1.0b
Median age of patient 56 (IQI = 25-69) 54 (IQI = 19-81) 0.87c
Form of scleroderma Diffuse – 27.3% (3/11) Diffuse – 35.5% (16/45) 1.00b
Limited – 72.7% (8/11) Limited – 64.4% (29/45)
Tabagism 45.5% (5/11) 38.1% (16/42) 0.73b
Raynaud 100%(11/11) 97.5% (44/45) 1.0b
Stellate ulceration 54.4%(6/11) 62.2% (28/45) 0.73b
Digital necrosis 10% (1/10) 13.3% (6/45) 0.62b
Teleangiectasias 20% (2/10) 40.9% (18/44) 0.29b
Rodnan (median) 11 (IIQ = 0-28) 15 (IIQ = 0-50) 0.22c
Myositis 18.2% (2/11) 14% (6/43) 0.66b
Arthritis 27.3% (3/11) 12.2% (19/45) 0.17b
Arthralgia 27.3% (3/11) 58.1% (25/43) 0.09b
Xerostomia 54.5% (6/11) 46.3% (19/41) 0.74b
Xerophthalmia 45.5% (5/11) 33.3% (14/42) 0.49b
Esophageal dysmotility 70% (7/11) 51.2% (22/43) 0.3b
Interstitial lung disease 63.6% (7/11) 30.2% (13/43) 0.07b
Pulmonary hypertension 66.7% (6/9) 22.5% (9/40) 0.01b
Myocarditis 0 0 -
Renal crisis 9.1% (1/11) 4.5% (2/44) 0.45b
Medsger (median) 5.5 (IIQ = 3-12) 5 (IIQ = 1-15) 1c
FAN 100% (11/11) 86.7% (39/45) 0.33b
Scl-70 0 18.2% (8/44) 0.18b
Anti-centromer 40% (4/10) 19% (8/42) 0.21b
Anti-Ro 18.2% (2/11) 17.8% (8/45) 1.0b
Anti-La 9.1% (1/11) 7.1% (3/42) 1.0b
IQI, Interquartile interval.
a Chi-squared.
b Fischer’s test.
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ackground on which environmental factors act.1 Several
tudies have shown that smoking, deﬁciency of vitamin D,
iet, ultraviolet light, drugs and viral infections can function as
nvironmental triggers for autoimmunity in genetically pre-
isposed subjects.1
It was observed in the present study a high prevalence
f HT in SSc patients (20%), which conﬁrms the ﬁnding of
he coexistence of autoimmune diseases. A knowledge of this
ssociation is of fundamental importance to the clinician that,
n treating an autoimmune disease, remains alert to other
nes. Moreover, the symptoms presented by a patient with HT
nd hypothyroidism and SSc can be confused with each other,
specially in the case of those most nonspeciﬁc symptoms,
uch as tiredness, fatigue, muscular weakness, anorexia and
rthralgia.16 These must be properly attributed to the causal
lement, in order to treat the patient adequately.
Avouac et al.,4 studying patients of European origin, found
hat SSc patients with other concomitant autoimmune dis-
ase appeared to have a milder SSc, associated with the
imited form of presentation. In the present analysis, these
ndings could not be conﬁrmed. However, it is important
o note that the authors above included in his work sev-
ral organ-speciﬁc autoimmune diseases, such as Sjögren’s
yndrome, myositis, systemic lupus erythematosus, andthyroiditis, and not only HT as in our study, which may explain
the difference in ﬁndings.
Still in the current sample, HT patients had a higher
prevalence of pulmonary arterial hypertension (PAH). The
association between hypothyroidism and primary pulmonary
hypertension had been noted previously.17–19 Opravil et al.20
also reported an increase in the prevalence of hypothyroidism
in patients with HIV and PAH, conﬁrming the possible associ-
ation between these two entities in another context.
Thyroid dysfunction has been associated with alter-
ations in vasoreactivity, a phenomenon that precedes PAH.21
Vasospasm causing Raynaud’s phenomenon has been found
in patients with isolated hypothyroidism and responds to
treatment with levothyroxine, which again suggests an
intriguing relationship between this hormone and the sta-
bilization of vascular reactivity.22 Furthermore, in animal
models, hypothyroidism has been shown to cause increases in
the levels of endothelin-1, a potent vasoconstrictor that con-
tributes to the pathogenesis of PAH,23,24 and to the pulmonary
hypertension of SSc.25 If this association will prove true, the
treatment of hypothyroidism would affect the results obtained
in the treatment of pulmonary hypertension, a well-known
risk complication, with high potential for morbidity and mor-
tality. Pressure changes in pulmonary artery, secondary to
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the thyroid dysfunction, respond to the treatment of the
endocrine disease.26
In this analysis, we  observed a trend of positive associa-
tion of HT with interstitial lung disease and a trend towards a
negative association with arthralgias. Interestingly, the liter-
ature describes cases of association of patients with HT and
interstitial lung disease, regardless of the existence of SSc.27,28
There are limitations to this study: one of them is the small
number of SSc patients studied. The second is the fact that
not all patients had catheterization in the right side of the
heart, and so their pulmonary artery pressures is estimated
by echocardiography. However, from a clinical standpoint,
the association found is very important and deserves further
research with larger numbers of patients.
In conclusion, it can be said that in the present study we
found a prevalence of HT in about 20% of the SSc population.
Larger studies are needed to clarify the deﬁnitive role of this
association with PAH.
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